IFITM3 blocks influenza virus entry by sorting lipids and stabilizing hemifusion.

IFITM3 continuum membrane modeling in situ cryo-ET influenza A virus innate immunity lipid sorting membrane fusion molecular dynamics simulations subtomogram averaging viral entry

Journal

Cell host & microbe
ISSN: 1934-6069
Titre abrégé: Cell Host Microbe
Pays: United States
ID NLM: 101302316

Informations de publication

Date de publication:
12 04 2023
Historique:
received: 06 07 2022
revised: 15 11 2022
accepted: 06 03 2023
medline: 17 4 2023
pubmed: 2 4 2023
entrez: 1 4 2023
Statut: ppublish

Résumé

Interferon-induced transmembrane protein 3 (IFITM3) inhibits the entry of numerous viruses through undefined molecular mechanisms. IFITM3 localizes in the endosomal-lysosomal system and specifically affects virus fusion with target cell membranes. We found that IFITM3 induces local lipid sorting, resulting in an increased concentration of lipids disfavoring viral fusion at the hemifusion site. This increases the energy barrier for fusion pore formation and the hemifusion dwell time, promoting viral degradation in lysosomes. In situ cryo-electron tomography captured IFITM3-mediated arrest of influenza A virus membrane fusion. Observation of hemifusion diaphragms between viral particles and late endosomal membranes confirmed hemifusion stabilization as a molecular mechanism of IFITM3. The presence of the influenza fusion protein hemagglutinin in post-fusion conformation close to hemifusion sites further indicated that IFITM3 does not interfere with the viral fusion machinery. Collectively, these findings show that IFITM3 induces lipid sorting to stabilize hemifusion and prevent virus entry into target cells.

Identifiants

pubmed: 37003257
pii: S1931-3128(23)00109-9
doi: 10.1016/j.chom.2023.03.005
pii:
doi:

Substances chimiques

Lipids 0
IFITM3 protein, human 0
Membrane Proteins 0
RNA-Binding Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

616-633.e20

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Steffen Klein (S)

Schaller Research Group, Department of Infectious Diseases, Virology, Heidelberg University Hospital, 69120 Heidelberg, Germany; BioQuant Center for Quantitative Biology, Heidelberg University, 69120 Heidelberg, Germany.

Gonen Golani (G)

BioQuant Center for Quantitative Biology, Heidelberg University, 69120 Heidelberg, Germany; Institute for Theoretical Physics, Heidelberg University, 69120 Heidelberg, Germany.

Fabio Lolicato (F)

Heidelberg University Biochemistry Center, Heidelberg University, 69120 Heidelberg, Germany; Department of Physics, University of Helsinki, Helsinki, Finland.

Carmen Lahr (C)

Schaller Research Group, Department of Infectious Diseases, Virology, Heidelberg University Hospital, 69120 Heidelberg, Germany; BioQuant Center for Quantitative Biology, Heidelberg University, 69120 Heidelberg, Germany.

Daniel Beyer (D)

Heidelberg University Biochemistry Center, Heidelberg University, 69120 Heidelberg, Germany.

Alexia Herrmann (A)

Heidelberg University Biochemistry Center, Heidelberg University, 69120 Heidelberg, Germany.

Moritz Wachsmuth-Melm (M)

Schaller Research Group, Department of Infectious Diseases, Virology, Heidelberg University Hospital, 69120 Heidelberg, Germany; BioQuant Center for Quantitative Biology, Heidelberg University, 69120 Heidelberg, Germany.

Nina Reddmann (N)

Schaller Research Group, Department of Infectious Diseases, Virology, Heidelberg University Hospital, 69120 Heidelberg, Germany; BioQuant Center for Quantitative Biology, Heidelberg University, 69120 Heidelberg, Germany.

Romy Brecht (R)

Schaller Research Group, Department of Infectious Diseases, Virology, Heidelberg University Hospital, 69120 Heidelberg, Germany; BioQuant Center for Quantitative Biology, Heidelberg University, 69120 Heidelberg, Germany.

Mehdi Hosseinzadeh (M)

Schaller Research Group, Department of Infectious Diseases, Virology, Heidelberg University Hospital, 69120 Heidelberg, Germany; BioQuant Center for Quantitative Biology, Heidelberg University, 69120 Heidelberg, Germany.

Androniki Kolovou (A)

Schaller Research Group, Department of Infectious Diseases, Virology, Heidelberg University Hospital, 69120 Heidelberg, Germany; BioQuant Center for Quantitative Biology, Heidelberg University, 69120 Heidelberg, Germany.

Jana Makroczyova (J)

Schaller Research Group, Department of Infectious Diseases, Virology, Heidelberg University Hospital, 69120 Heidelberg, Germany; BioQuant Center for Quantitative Biology, Heidelberg University, 69120 Heidelberg, Germany.

Sarah Peterl (S)

Schaller Research Group, Department of Infectious Diseases, Virology, Heidelberg University Hospital, 69120 Heidelberg, Germany; BioQuant Center for Quantitative Biology, Heidelberg University, 69120 Heidelberg, Germany.

Martin Schorb (M)

Electron Microscopy Core Facility, European Molecular Biology Laboratory, 69117 Heidelberg, Germany.

Yannick Schwab (Y)

Electron Microscopy Core Facility, European Molecular Biology Laboratory, 69117 Heidelberg, Germany.

Britta Brügger (B)

Heidelberg University Biochemistry Center, Heidelberg University, 69120 Heidelberg, Germany.

Walter Nickel (W)

Heidelberg University Biochemistry Center, Heidelberg University, 69120 Heidelberg, Germany.

Ulrich S Schwarz (US)

BioQuant Center for Quantitative Biology, Heidelberg University, 69120 Heidelberg, Germany; Institute for Theoretical Physics, Heidelberg University, 69120 Heidelberg, Germany.

Petr Chlanda (P)

Schaller Research Group, Department of Infectious Diseases, Virology, Heidelberg University Hospital, 69120 Heidelberg, Germany; BioQuant Center for Quantitative Biology, Heidelberg University, 69120 Heidelberg, Germany. Electronic address: petr.chlanda@bioquant.uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH